UNSPSC 51313506: Eclazolast

This classification denotes a histamine-1 receptor antagonist with the molecular formula C12H12ClNO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R5ELL4R7VD, chemically known as 2-benzoxazolecarboxylic acid, 5-chloro-, 2-ethoxyethyl ester but generally known as eclazolast, which bears US NIH Compound Identifier 54550. European Medicines Agency schedules Eclazolast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06448MIG.

UNSPSC 51313506 Eclazolast is a Commodity code that sits at the narrowest tier of the taxonomy, yet the recent state and local solicitations tagged with this code do not center on eclazolast itself — instead, they reflect procurement of naloxone, safe drug deactivation systems, generic pharmaceuticals, and over-the-counter products. The code's application appears misaligned with the work actually being solicited; state and local governments are buying emergency-response medications, pharmacy benefit management services, and multi-source generic and OTC inventory through cooperative purchasing vehicles and direct procurement, not the specific pharmaceutical compound the code names. Issuing bodies range from county health departments to state health and human services commissions, with cooperative purchasing alliances managing multi-jurisdictional contracts. Seminole County, Florida issued an IFB for annual naloxone and drug deactivation systems procurement, while the Texas Health and Human Services Commission issued an RFI to explore direct-to-manufacturer prescription fulfillment capabilities, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration released an RFP for generic multi-source pharmaceuticals and OTC products spanning multiple states including Oregon.

Recent activity shows geographic concentration in Florida, Texas, and the upper Midwest, with MMCAP's multi-state cooperative vehicle connecting Oregon and other participating jurisdictions. Seminole County's IFB (posted June 30, 2026, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with electronic bid submission required and a two-year initial contract term plus one-year renewal option. The Texas HHS RFI (posted April 3, 2026, response deadline April 3, 2026) requested vendor information on direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager and group purchasing organization channels, designed as exploratory work before formal RFP issuance. The MMCAP RFP (posted January 20, 2026, due March 26, 2026) required vendors to supply generic pharmaceuticals and OTC products through three authorized wholesalers, with product availability by May 15, 2026 and contract effectiveness July 1, 2026; evaluation weighted price competitiveness at 75 percent and required cGMP and Drug Supply Chain Security Act compliance. The code shows recent activity but limited relevance to eclazolast specifically; procurement professionals should verify tagging accuracy before pursuing opportunities under this code.